We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AAM: Exclusionary Biologics Contracts Will Hurt Emerging Biosimilars Market
AAM: Exclusionary Biologics Contracts Will Hurt Emerging Biosimilars Market
The Association for Accessible Medicines’ Biosimilars Council submitted an amicus brief supporting Pfizer in its antitrust lawsuit against Johnson & Johnson, arguing the company’s practices will keep biologics prices high and limit competition from biosimilars.